WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call
You may also be interested in...
Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger
BEIJING - Like a prospective bride who has been jilted at the very last moment by a suitor, Shanghai's WuXi PharmaTech has been abandoned by the Massachusetts-headquartered Charles River Laboratories on the eve of the two contract research organizations' merger
China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference
BEIJING - China's status as an observer country in the Organization for Economic Cooperation and Development will help the local contract research organization sector get faster access to the world's top biomedical markets for drugs developed and tested in China, said leaders at DIA's China conference May 19
China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit
BEIJING - Just days after disclosing that a newly launched drug safety testing center had been accredited by a U.S. group, leading Chinese contract research organization Wuxi PharmaTech signed a toxicology deal with Johnson & Johnson Pharmaceutical Research & Development